Dyadic International Inc (DYAI): Total Assets
$9.95M
As of 2025-12-31
$6.54M
As of 2026-06-30
-10.2%
3-year compound annual growth
-19.9%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.95M | +0.2% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $9.93M | +20.8% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $8.22M | -40.1% | 2025-03-26, Balance as of period end |
| 2022-12-31 | $13.71M | -35.6% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $21.30M | -29.2% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $30.07M | -19.7% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $37.45M | -13.5% | 2021-03-30, Balance as of period end |
| 2018-12-31 | $43.30M | -14.7% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $50.74M | n/a | 2019-03-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Dyadic International Inc (DYAI) | 2025-12-31 | $9.95M | +0.2% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $98.73M | +103.7% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $2.27B | +1.0% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $791.59M | +4.9% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $88.53M | +26.3% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $43.52M | -47.2% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $342.73M | +15.2% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $116.37M | -15.6% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $1.53M | -7.1% |
Compare DYAI, SRZN, CRSP, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗